Zydus Lifesciences Receives Us Fda Approval For Antidepressant Drugs

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Zydus Lifesciences receives US FDA approval for antidepressant drugs

ri-calendar-2-lineAug 18, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Zydus Lifesciences, a pharmaceutical company, stated that its Doxepin tablets have gained final approval from the US Food and Drug Administration (USFDA).

 

The company has acquired final approval to sell its Doxepin Tablets in 3 mg and 6 mg variants. The medication, which belongs to the class of tricyclic antidepressants, is used to treat sleep problems such as insomnia. The medication is intended to increase sleep duration and decrease nighttime awakenings.

 

According to a source provided by the company, Doxepin has yearly sales of $43.4 million in the United States. The medicines will be manufactured at the company's formulation production plant in Moraiya, Gujarat, according to the company.

 

With this latest approval, Zydus' total number of USFDA approvals now stands at 376. Since the beginning of the filing procedure in the fiscal year 2003-04, the company has filed over 444 abbreviated new medicine applications with the drug regulator.

 

Source: Media Reports

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions